CytoMed Therapeutics Limited announced the publication of preclinical study results demonstrating the promising therapeutic potential of its allogeneic γδ T cell therapy for treating acute myeloid leukemia (AML). The research, conducted in collaboration with The University of Texas MD Anderson Cancer Center, was published in a study entitled "Donor-Derived Vγ9Vδ2 T Cells for Acute Myeloid Leukemia: A Promising 'off-the-shelf' Immunotherapy Approach."
Collaborative Research Yields Promising Results
The preclinical study results suggest the promising potential of CytoMed's allogeneic γδ T cell therapy (CTM-GDT) for treating AML. This collaboration with MD Anderson stems from a research agreement announced in May 2023, highlighting the company's strategic partnerships with leading cancer research institutions.
"These findings provide the rationale for further clinical study of allogeneic donor-derived γδ T cells in treating AML as well as other cancers," said Dr. Zeng Jieming, M.D., Ph.D., Chief Scientific and Medical Officer of CytoMed and co-author of the paper. "It will facilitate our endeavour to advance our next γδ T cell-based product into clinical trial after our leading product CAR-γδ T cells (CTM-N2D), which is currently undergoing a Phase 1 clinical trial in Singapore."
Clinical Development Pipeline
The published research supports CytoMed's broader immunotherapy development strategy. The company is currently conducting a Phase 1 clinical trial of its leading CAR-γδ T cell product (CTM-N2D) in Singapore, with plans to advance additional γδ T cell-based therapies into clinical testing based on these preclinical findings.
Peter Choo, Chairman of CytoMed, commented on the research implications: "This research provides more evidence for applying allogeneic γδ T cells to hematologic malignancies and we are planning to move into clinical trials in Southeast Asia and bring novel immunotherapy options to patients with limited treatment alternatives."
Company Background and Technology Platform
CytoMed Therapeutics, incorporated in 2018 and spun off from Singapore's Agency for Science, Technology and Research (A*STAR), focuses on developing novel cell-based allogeneic immunotherapies. The company harnesses proprietary technologies including gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell platforms to treat various human cancers, including both blood and solid tumors.
The development of CytoMed's novel technologies has been inspired by the clinical success of existing CAR-T therapies in treating hematological malignancies, while addressing current clinical limitations and commercial challenges in applying CAR-T principles to solid tumor treatment. The company's approach aims to provide affordable donor-derived cell-based immunotherapies as an "off-the-shelf" solution for cancer treatment.
